Cargando…

CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome

BACKGROUND: Li-Fraumeni syndrome (LFS) is characterized as an autosomal dominant cancer predisposition disorder caused by germline TP53 gene mutations. Both primary and therapy-related hematopoietic malignancies with LFS are associated with dismal outcomes with standard therapies and even allogenic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Liting, Xu, Bin, Long, Xiaolu, Gu, Jia, Lou, Yaoyao, Wang, Di, Cao, Yang, Wang, Na, Li, Chunrui, Wang, Gaoxiang, Wang, Ying, Zhu, Li, Wang, Jin, An, Haiyun, Xiao, Min, Xiao, Yi, Zhou, Jianfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213909/ https://www.ncbi.nlm.nih.gov/pubmed/32345625 http://dx.doi.org/10.1136/jitc-2019-000364

Ejemplares similares

Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report
por: Liu, Wanying, et al.
Publicado: (2022)

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
por: Li, Chunrui, et al.
Publicado: (2021)

A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy
por: Mu, Wei, et al.
Publicado: (2022)

CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Progressive Muscular Dystrophy: A Case Report
por: Chen, Liting, et al.
Publicado: (2022)

Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study
por: Wang, Songmi, et al.
Publicado: (2023)

Li-Fraumeni Syndrome
por: Vogel, Wendy H.
Publicado: (2017)

Long‐term outcomes of relapsed/refractory double‐hit lymphoma (r/r DHL) treated with CD19/22 CAR T‐cell cocktail therapy
por: Wei, Jia, et al.
Publicado: (2020)

Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li–Fraumeni syndrome
por: Winter, Greta, et al.
Publicado: (2021)

TP53-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy
por: Chen, Liting, et al.
Publicado: (2021)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas
por: Xu, Hao, et al.
Publicado: (2023)

Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials
por: Que, Yimei, et al.
Publicado: (2021)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma
por: Zhang, Peiling, et al.
Publicado: (2022)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022)

Treatment and Response Evaluation Challenges in a Pregnant Woman With B-Cell Lymphoblastic Leukemia and Li-Fraumeni Syndrome
por: Erikstein, Bjarte Skoe, et al.
Publicado: (2023)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Hematologic malignancies and Li–Fraumeni syndrome
por: Swaminathan, Mahesh, et al.
Publicado: (2019)

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
por: Vairy, Stephanie, et al.
Publicado: (2018)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Wang, Linqin, et al.
Publicado: (2021)

The first documentation of Li-Fraumeni syndrome in Korea.
por: Bang, Y. J., et al.
Publicado: (1995)

Pediatric Case of Li–Fraumeni Syndrome in Honduras
por: Martínez-Beckerat, R., et al.
Publicado: (2021)

Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome
por: Pantziarka, Pan, et al.
Publicado: (2022)

A Case of Li-Fraumeni Associated Thymoma
por: Sivayoganathan, Thibacg, et al.
Publicado: (2022)

Arsenic trioxide extends survival of Li–Fraumeni syndrome mimicking mouse
por: Li, Jiabing, et al.
Publicado: (2023)

A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma
por: Wang, Di, et al.
Publicado: (2023)

Li-Fraumeni syndrome--a molecular and clinical review.
por: Varley, J. M., et al.
Publicado: (1997)

Li-Fraumeni Syndrome: A Rare Genetic Disorder
por: Tazin, Faria, et al.
Publicado: (2022)

CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
por: Zhang, Li-Na, et al.
Publicado: (2018)

Successful Treatment of Refractory and Relapsed CNS Acute Lymphoblastic Leukemia With CD-19 CAR-T Immunotherapy: A Case Report
por: Htun, Kyaw Thu, et al.
Publicado: (2021)

Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity
por: Zhang, Na, et al.
Publicado: (2022)

Case report of a Li–Fraumeni syndrome-like phenotype with a de novo mutation in CHEK2
por: Zhuang, Xuehan, et al.
Publicado: (2016)

Li‐Fraumeni versus Pseudo‐Li‐Fraumeni Syndrome: Key Insights for Interpreting Next‐Generation Sequencing Reports in Patients with Suspected Cancer Predisposition Syndromes
por: Sorscher, Steven, et al.
Publicado: (2017)

Genetic and functional analysis of a Li Fraumeni syndrome family in China
por: Hu, Huaying, et al.
Publicado: (2016)

Li-Fraumeni syndrome: a case report from Italy.
por: Orjuela, M., et al.
Publicado: (1990)

Li Fraumeni syndrome, cancer and senescence: a new hypothesis
por: Pantziarka, Pan
Publicado: (2013)

PEComa in a Young Patient with Known Li-Fraumeni Syndrome
por: Neofytou, Kyriakos, et al.
Publicado: (2015)

Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche
por: Pantziarka, Pan
Publicado: (2015)

Prostate Cancer and Li-Fraumeni Syndrome: Implications for Screening and Therapy
por: Spees, Colleen K., et al.
Publicado: (2015)

The Features of Colorectal Tumors in a Patient with Li-Fraumeni Syndrome
por: Yoshida, Tsukasa, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5jpdkbvjj0fbhdkp3n5clk7gih